# Schizophrenia: Diagnosis, Neurobiology, and the Dopamine Hypothesis

## Diagnosis

### DSM-5-TR Criteria

Two or more of the following, each present for a significant portion of a 1-month period (at least one must be 1, 2, or 3): Delusions. Hallucinations. Disorganized speech. Grossly disorganized or catatonic behavior. Negative symptoms (diminished emotional expression or avolition) Continuous signs of disturbance for at least 6 months (including prodromal and residual phases with attenuated symptoms) Significant functional decline from premorbid level. Schizoaffective disorder and depressive/bipolar disorder with psychotic features have been ruled out. Not attributable to substance use or another medical condition.

### Symptom Domains

| Symptom Domain | Examples | Treatment Responsiveness | Functional Impact |
|----------------|----------|-------------------------|-------------------|
| Positive | Hallucinations, delusions, thought disorder | Good (antipsychotic D2 blockade) | Moderate |
| Negative | Blunted affect, alogia, avolition, anhedonia, asociality | Poor (no FDA-approved treatment) | High |
| Cognitive | Attention, working memory, processing speed, executive function deficits | Poor (limited pharmacotherapy) | Highest (strongest predictor of outcome) |
| Mood | Depression (40-50% comorbidity), anxiety | Moderate (antidepressants as adjuncts) | Contributes to suicide risk |

**Positive symptoms:** hallucinations (auditory most common, often commanding or commenting voices), delusions (persecutory, referential, grandiose, bizarre), thought disorder (tangentiality, derailment, neologisms) **Negative symptoms:** blunted affect, alogia (poverty of speech), avolition (lack of motivation), anhedonia, asociality. Primary negative symptoms: intrinsic to the illness. Secondary negative symptoms: caused by medication side effects (EPS/sedation), depression, social deprivation, substance use -- must be ruled out before attributing to illness. **Cognitive symptoms:** deficits in attention, working memory, processing speed, executive function; present in ~75% of patients; strongest predictor of functional outcome. **Mood symptoms:** depression is common (comorbid in 40-50% of patients); contributes to suicide risk.

### Diagnostic Stability

Schizophrenia diagnosis is highly stable once established (>80% retain diagnosis at 10-year follow-up) First-episode patients may receive provisional diagnoses; longitudinal assessment is essential. Diagnostic instability is more common at the boundary with schizoaffective and bipolar disorders. Early-onset (<18 years) and very-late-onset (>40 years) schizophrenia have distinct clinical features.

## Neurobiology

### The Dopamine Hypothesis

#### Classical Dopamine Hypothesis (Version 1)

Proposed in the 1960s based on two observations: Amphetamines (increase dopamine) can induce psychotic symptoms. Antipsychotic efficacy correlates with D2 receptor binding affinity (Seeman & Lee 1975) Original formulation: schizophrenia = excessive dopaminergic activity.

#### Modified Dopamine Hypothesis (Version 2)

**Mesolimbic pathway hyperactivity:** excessive dopamine in the ventral tegmental area (VTA) to nucleus accumbens/limbic structures -- drives positive symptoms. **Mesocortical pathway hypoactivity:** insufficient dopamine to the prefrontal cortex -- drives negative symptoms and cognitive deficits. Explains why D2 blockade treats positive symptoms but may worsen negative/cognitive symptoms. Supported by PET imaging studies showing elevated presynaptic dopamine synthesis capacity in the striatum.

#### Aberrant Salience Model (Version 3 -- Kapur)

Dysregulated mesolimbic dopamine leads to abnormal assignment of salience to neutral stimuli. Patients experience everyday events as personally relevant, threatening, or meaningful when they are not. Delusions arise as the cognitive framework constructed to explain these aberrant salience experiences. Antipsychotics reduce dopaminergic salience signaling, allowing "dampening" of psychotic experiences.

### The Glutamate Hypothesis

Based on the observation that NMDA receptor antagonists (PCP, ketamine) produce symptoms closely resembling schizophrenia -- including negative and cognitive symptoms (unlike dopamine agonists which primarily produce positive symptoms) NMDA receptor hypofunction on GABAergic interneurons leads to cortical disinhibition and downstream dopamine dysregulation. May explain negative and cognitive symptoms better than the dopamine hypothesis alone. Glutamate-based therapeutics are under development but none are FDA-approved.

### Neurodevelopmental Model

Schizophrenia is increasingly understood as a neurodevelopmental disorder with genetic and environmental risk factors interacting during brain development. **Prenatal risk factors:** maternal infection (influenza, toxoplasmosis), obstetric complications, maternal malnutrition, maternal stress. **Childhood/adolescent risk factors:** childhood trauma, cannabis use (especially during adolescence), urbanicity, migration/social adversity. **Genetic architecture:** highly polygenic (>200 risk loci identified by GWAS); common variants explain ~25% of variance; rare CNVs (22q11 deletion, 1q21, 15q13) confer higher individual risk. **Synaptic pruning hypothesis:** excessive synaptic pruning during adolescence (complement system-mediated, C4A gene) may underlie cortical thinning and onset of illness in late adolescence/early adulthood.

### Structural and Functional Neuroimaging

**Structural MRI findings:** enlarged lateral ventricles (most replicated finding), reduced cortical gray matter volume (particularly prefrontal and temporal cortex), reduced hippocampal volume. Gray matter loss is progressive, especially in early illness -- supports the importance of early intervention. **Functional MRI:** reduced DLPFC activation during working memory tasks; abnormal default mode network connectivity; altered salience network activity. **PET imaging:** elevated presynaptic dopamine synthesis capacity in the striatum (fluorodopa PET); this finding is specific to schizophrenia vs. other psychotic disorders. Neuroimaging findings are group-level and are NOT diagnostic in individual patients.

<image>
A dual-panel diagram of the dopamine pathways in the brain. Panel 1 shows normal dopamine function in the four major pathways: mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular. Panel 2 shows the altered dopamine state in schizophrenia: mesolimbic hyperactivity (highlighted in red, labeled "positive symptoms"), mesocortical hypoactivity (highlighted in blue, labeled "negative and cognitive symptoms"), with arrows showing where antipsychotic D2 blockade acts. Include labels for VTA, nucleus accumbens, prefrontal cortex, striatum, and pituitary. Neuroscience illustration style.
</image>

<image>
A schematic showing the neurodevelopmental model of schizophrenia. Use a timeline from prenatal period through adolescence to adulthood. Mark genetic risk factors (polygenic risk, rare CNVs), prenatal environmental hits (infection, obstetric complications), childhood risk factors (trauma, cannabis), adolescent synaptic pruning (with C4A annotation), and the emergence of prodromal and then full psychotic symptoms in late adolescence/early adulthood. Show the cumulative threshold model where combined genetic and environmental risk crosses the illness threshold. Developmental neuroscience illustration.
</image>

<image>
A brain imaging composite showing key structural and functional findings in schizophrenia. Include: (1) axial MRI slice showing enlarged lateral ventricles, (2) cortical thickness map showing prefrontal and temporal thinning, (3) schematic of PET findings showing elevated striatal dopamine synthesis, (4) functional connectivity diagram showing DLPFC hypoactivation and altered default mode network. Label each finding with the associated symptom domain and the evidence level. Medical imaging reference style.
</image>

## Clinical Pearls

The 6-month duration criterion distinguishes schizophrenia from brief psychotic disorder (<1 month) and schizophreniform disorder (1-6 months) -- do not rush the diagnosis. Negative and cognitive symptoms are the strongest predictors of functional outcome, yet they are the most difficult to treat pharmacologically. Secondary negative symptoms (from medication side effects, depression, or substance use) must be systematically excluded before attributing them to the primary illness. The dopamine hypothesis explains positive symptoms well but is incomplete -- the glutamate hypothesis better accounts for negative and cognitive features. Cannabis use during adolescence is a modifiable risk factor for schizophrenia in genetically vulnerable individuals -- educate patients and families. Progressive gray matter loss in early schizophrenia supports the urgency of early intervention and minimizing the duration of untreated psychosis. Neuroimaging is useful for research and for excluding structural pathology at first presentation, but no scan can diagnose schizophrenia.

## References

- Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III -- the final common pathway. *Schizophr Bull*. 2009;35(3):549-562.
- Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. *Am J Psychiatry*. 2003;160(1):13-23.
- Ripke S, et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.
- Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. *Nature*. 2016;530(7589):177-183.
- van Erp TG, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium. *Biol Psychiatry*. 2018;84(9):644-654.
- Howes OD, et al. Glutamate and dopamine in schizophrenia: an update for the 21st century. *J Psychopharmacol*. 2015;29(2):97-115.